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Severe Acute Respiratory Syndrome (SARS) is a highly contagious infectious disease which 23 
first emerged in late 2002, caused by a then novel human coronavirus, SARS coronavirus (SARS-24 
CoV). The virus is believed to have originated from bats and transmitted to human through 25 
intermediate animals such as civet cats. The re-emergence of SARS-CoV remains a valid concern due 26 
to the continual persistence of zoonotic SARS-CoVs and SARS-like CoVs (SL-CoVs) in bat 27 
reservoirs. In this study, the screening for the presence of SARS-specific T cells in a cohort of three 28 
SARS-recovered individuals at 9 and 11 years post-infection was carried out, and all memory T cell 29 
responses detected target the SARS-CoV structural proteins. Two CD8
+
 T cell responses targeting the 30 
SARS-CoV membrane (M) and nucleocapsid (N) proteins were characterized by determining their 31 
HLA restriction and minimal T cell epitope regions. Furthermore, these responses were found to 32 
persist up to 11 years post-infection. An absence of cross-reactivity of these CD8
+
 T cell responses 33 
against the newly-emerged Middle East Respiratory Syndrome coronavirus (MERS-CoV) was also 34 
demonstrated. The knowledge of the persistence of SARS-specific celullar immunity targeting the 35 
viral structural proteins in SARS-recovered individuals is important in the design and development of 36 
SARS vaccines, which are currently unavailable.   37 
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1. Introduction 48 
Severe Acute Respiratory Syndrome (SARS) first emerged 12 years ago as a highly 49 
contagious infectious disease, caused by a then novel human coronavirus, termed SARS coronavirus 50 
(SARS-CoV) [1]. The virus spread to 25 countries in a short period of three months, affecting a total 51 
of 8098 people globally including 774 deaths, a fatality rate of 10% [2]. SARS-CoV is believed to 52 
have originated from bats [3-5] and transmitted to human through intermediate animals such as civet 53 
cats [6]. Although no SARS cases have been reported since 2004, the re-emergence of SARS-CoV is 54 
of public health concern due to the continual persistence of SARS-CoVs and SARS-like CoVs (SL-55 
CoVs) in bat reservoirs.  The SARS-CoV is classified in the order Nidovirales, family Coronaviridae 56 
and genus betacoronavirus (lineage B). It is an enveloped, positive-sense and single-stranded RNA 57 
virus of a genome size of 29.7 kb, encoding 16 non-structural proteins (nsps), 4 structural proteins 58 
(spike [S], membrane [M], nucleocapsid [N], envelope [E]) and 8 accessory proteins (3a, 3b, 6, 7a, 7b, 59 
8a, 8b, 9) proteins [7].  60 
Animal studies have indicated the importance of T cells in the clearance of SARS-CoV 61 
during primary infection and protection from disease [8-10]. In humans, decreased T cell numbers 62 
(lymphopenia) correlated with severe disease, indicating the critical role of T cell-mediated immune 63 
response in disease development [11, 12]. While SARS-specific antibody level in SARS-recovered 64 
individuals is undetectable at 6 years post-infection, SARS-specific memory T cells persisted up to 6 65 
years following recovery [13]. The long-term persistence of memory T cell immunity could be 66 
important in protection against SARS-CoV re-infection. In this study, the presence of SARS-specific 67 
T cells was screened in three SARS-recovered individuals at 9 and 11 years post-infection. The 68 
characterization of CD8
+ 
T cell responses against the structural M and N proteins was carried out, 69 
including the determination of HLA restriction and the minimal T cell epitope. In addition, cross-70 
reactivity of SARS-specific CD8
+
 T cells against the Middle East Respiratory Syndrome coronavirus 71 
(MERS-CoV) was investigated.  72 
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2. Materials and methods 73 
2.1. Synthetic peptides  74 
A total of 550 peptides were purchased from Chiron Mimotopes (Victoria, Australia) at purity 75 
above 80% and their compositions were confirmed by mass spectrometry. The peptides are 15-mers 76 
overlapping by 10 residues spanning the proteome of SARS-CoV structural (S, E, M, N) and 77 
accessory (3a, 3b, 6, 7a, 7b, 8a, 8b, 9) proteins. Peptides were received in lyophilized forms and 78 
diluted at 40 mg/ml in dimethyl sulfoxide (DMSO) and then further diluted in RPMI medium 79 
(Gibco®) at working concentrations of 10 mg/ml to 1 mg/ml.  80 
2.2. Collection of blood samples from SARS-recovered subjects  81 
Three SARS-recovered individuals were enrolled from the Singapore General Hospital, 82 
Singapore. All participants were diagnosed with SARS during the period of 2003 according to World 83 
Health Organization’s definition of SARS [14]. Blood samples were obtained at either 9 or 11 years 84 
post-infection. This study was approved by the Singhealth Centralized Institutional Review Board 85 
(Singapore).  86 
2.3. PBMC isolation and in vitro expansion of SARS-specific T cells  87 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh heparinized blood by 88 
density gradient centrifugation using Ficoll-Paque
TM 
(GE Life Sciences) and resuspended in AIM-V 89 
medium (Invitrogen) with 2% pooled human AB serum (AIM-V+2%AB). Cells were either frozen 90 
down or used directly for in vitro expansion in the presence of SARS peptides, as previously 91 
described [13].  92 
2.4. Anti-human IFNγ ELISpot assay  93 
Anti-human IFNγ enzyme-linked immunospot (ELISpot) assays were performed as 94 
previously described [13], using the SARS peptides arranged in numeric and alphabetic matrix pools 95 
5 
 
(Supplementary Table 1). The positive threshold was set at number of spot-forming units (SFU) per 5 96 
x 10
4 
cells at least twice of that observed in negative control (cells not stimulated with peptides). The 97 
peptide responsible for positive ELISpot results was identified as the common peptide present in both 98 
the numeric and alphabetic pools. 99 
2.5. Intracellular cytokine staining (ICS) and degranulation assays 100 
In vitro expanded PBMCs were incubated in AIM-V+2%AB medium alone or with peptides 101 
at 5 μg/ml for 5 hours in the presence of 10 μg/ml of brefeldin A. Anti-CD107a-FITC antibody (BD 102 
Pharmingen) was added for assessing CD8
+
 T cell degranulation. Positive control consisted of T cells 103 
incubated in AIM-V+2%AB with 10 ng/ml phorbol 12-myristate 13-acetate (PMA) and 100 ng/ml 104 
ionomycin. Following stimulation, cells were washed in Hank's Balanced Salt Solution (HBSS 105 
[Gibco®]) and stained with anti-CD8-phycoerythrin(PE)-Cy7 and anti-CD3-peridinin chlorophyll 106 
protein(PerCP)-Cy5.5 (BD Pharmingen) at 4
o
C. Cells were washed in 1x phosphate buffered saline 107 
(PBS) containing 1% BSA and 0.1% azide, fixed and permeabilized using Cytofix/Cytoperm 108 
fixation/permeabilization reagent (BD Biosciences) according to manufacturer’s protocol. 109 
Intracellular staining using anti-IFNγ-PE (BD Pharmingen) was carried out at 4oC, followed by 110 
washing and flow cytometry analysis.  111 
2.6. Human Leukocyte Antigen (HLA) restriction of CD8
+
 T cell responses  112 
HLA class I phenotypes of the SARS-recovered subjects was determined by PCR 113 
amplification and sequencing-based typing method as previously described [13] and as performed by 114 
BGI Clinical laboratories (ShenZhen, China). Epstein-Barr virus-transformed lymphoblastoid B cell 115 
lines (EBV-LCLs) possessing matching HLA phenotypes as the subjects were used as antigen-116 
presenting cells (APCs) to determine the HLA restriction of CD8
+
 T cell responses.  117 
2.7. Restimulation of SARS-specific CD8
+ 
T cells and minimal epitope mapping of CD8
+
 T cell 118 
epitopes  119 
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Restimulation of SARS-specific CD8
+
 T cells was done using fresh PBMCs from a healthy 120 
donor and EBV-LCL consisting of the HLA allele restricting the CD8
+
 T cell response. Specific 121 
peptide was added to EBV-LCL at 1 μg/ml in R10 medium and incubated at 37 oC for 1 hour, 122 
followed by washes with HBSS. PBMCs and the peptide-pulsed EBV-LCL were irradiated at 2500 123 
RADs and 4000 RADs respectively, washed with HBSS and added to in vitro expanded T cells in 124 
AIM-V+2%AB supplemented with IL-2 (20 U/ml), IL-7 (10 ng/ml) and IL-15 (10 ng/ml) and co-125 
cultured at 37
o
C for 10 days.  126 
For mapping of minimal T cell epitope, restimulated short-term T cell lines were tested with 127 
truncated peptides of the 15-mer peptide by ICS. For M29 minimal epitope mapping, 21 peptides (8-128 
mers to 12-mers) spanning the M29 region were tested. For N53 minimal epitope mapping, 6 peptides 129 
(8-mers to 10-mers) spanning the overlapping region of N53 and N54 were used.  130 
3. Results and Discussion  131 
3.1. Identification of SARS-specific memory T cell responses in SARS-recovered individuals at 9 132 
and 11 years post-infection 133 
As it is currently unknown if SARS-specific memory T cell responses persist in SARS-134 
recovered individuals after 6 years post-infection, PBMCs from a SARS convalescent subject (SARS 135 
subject 1) were collected at 9 years post-infection and tested for SARS-specific memory T cells. As  136 
negative control, PBMCs of a healthy individual with no SARS history were also obtained and tested. 137 
After in vitro expansion with the mixture of SARS 15-mer peptides of 10 overlapping residues 138 
spanning the structural (S, E, M, N) and accessory (3a, 3b, 6, 7a, 7b, 8a, 8b, 9b) proteins, the PBMCs 139 
were subjected to IFNγ ELISpot assay using SARS peptide pools arranged in alphabetic and numeric 140 
matices (Supplementary Table 1). Analysis of ELISpot results was performed with the positive 141 
threshold set as the number of spot-forming units (SFU) two times above the mean SFU of 142 
unstimulated cells. As shown in Figure 1, higher frequencies of IFNγ-producing SFUs were observed 143 
for in vitro-expanded PBMCs from SARS subject 1 compared to the healthy individual, suggesting 144 
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the presence of SARS-specific memory T cells at 9 years post-infection. These responses were low in 145 
frequency since in vitro expansion of PBMCs was required for their detection. This is in agreement 146 
with previous reports that reported the decline of memory T cell responses in SARS convalescent 147 
individuals over time [13, 15].  148 
Peptides inducing IFNγ production as identified from ELISpot were further tested by 149 





) involved. A total of 4 SARS-specific memory T cell responses were 151 
identified in SARS subject 1 and they are specific for structural S, N and M proteins (Table 152 
1). Three are CD4
+
 T cell responses, of which two recognized the S protein (S104 and S109) 153 
and one recognized the N protein (N21). In addition, CD8
+
 memory T cell response specific 154 
for the SARS-CoV M protein (M29) was detected. Subsequently, PBMCs were obtained 155 
from two other SARS-recovered individuals (SARS subject 2 and 3) at 9 and 11 years post-156 
infection respectively and screened for SARS-specific memory T cells using the same 157 
method. Memory T cell responses specific against SARS-CoV structural proteins were also 158 
found (Table 1). As with that observed in SARS subject 1, N21 CD4
+
 response and M29 159 
CD8
+
 response were found in SARS subject 2 and 3 respectively. SARS subject 3 also 160 
possessed a CD4
+
 T cell response targeting S217. As summarized in Table 1, subject 1 had 161 
more SARS-specific memory T cells at higher frequencies compared to the other two 162 
subjects. It was noted that subject 1 had more severe disease presentation (Supplementary 163 
Table 2), which could be related to the more robust T cell responses detected.  However, the 164 
number of subjects recruited in this study is too small to draw a conclusion to this 165 
correlation.The knowledge that SARS-CoV structural proteins are highly immunogenic in eliciting 166 
protective and immunodominant T cell responses is well-established [16-18]. The CD4
+ 
T cell 167 
epitopes identified here, which are specific against S104 (S protein residues 516-530), S109 (S protein 168 
residues 541-555), S217 (S protein residues 1081-1095) and N21 (N protein residues 101-115), have 169 
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been previously reported from a cohort of SARS-recovered patients at 1 year post-infection, 170 
suggesting the immunoprevalence and dominance of these responses in convalescent SARS patients 171 
[16]. Here, the identification of T cell responses against SARS-CoV structural S, N and M proteins at 172 
9 and 11 years post-infection suggests the long-term persistence of these responses.   173 
3.2. Characterization of SARS-specific M29 CD8
+
 T cell response  174 
The CD8
+
 T cell response present in SARS subject 1 and 3, which is specific for SARS 175 
peptide M29 corresponding to residues 141-155 of the structural M protein, was further characterized. 176 
Using T cells from subject 1, the M29 CD8
+
 T cell response was determined to be restricted by the 177 
HLA-B*1502 allele.  As revealed by ICS, M29-restimulated CD8
+
 T cells exhibited CD8
+IFNγ+ 178 
response at 27.6% when stimulated with M29 peptide (Figure 2, left panels). Additionally, CD107a 179 
expression of T cells induced by M29 peptide was determined to be 12.7% (Figure 2, right panels). 180 
The increase in CD107a expression, a marker for T cell degranulation and target cell-killing function 181 
via the perforin-granzyme pathway [19], indicates that the memory T cells were capable of 182 
degranulation and likely to exhibit target cell-killing function upon activation by M29 peptide. 183 
HLA class I molecules preferentially bind and present peptides of 8 to 11 amino acids to be 184 
recognized by HLA receptors on CD8
+
 T cells during T cell activation [20]. Since the M29 peptide is 185 
a 15-mer peptide, the identification of the position and minimal number of amino acids within the 186 
M29 region, known as the minimal epitope, capable in eliciting the M29 CD8
+ 
T cell response was 187 
carried out. To do so, truncated peptides within the M29 region ranging from 8- to 12-mers were 188 
tested for their abilities to induce IFNγ secretion by M29-restimulated T cells. As shown in Table 2, 189 
the 9-mer peptide, M29147-155, corresponding to residues 147-155 of M protein, was most efficient in 190 
inducing the CD8
+
 T cell response, resulting in the highest percentage of IFNγ-producing cells of 191 
32.9%. This 9-mer also represents the minimal epitope of M29 CD8
+
 T cell response, as the removal 192 
of either the N-terminus histidine (H) residue (M29148-155) or the C-terminus leucine (L) residue 193 
(M29145-154) completely abolished IFNγ production (Table 2).  194 
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In a study involving 128 SARS convalescent patients at 1 year post-infection, CD8
+
 T cell 195 
response against residues 146-160 of the M protein was present in 9% of study subjects, but the 196 
minimal epitope and the HLA-restriction of this response were not determined [16]. The M29 197 
minimal epitope (residues 147-155) identified in present study lies within this reported region. Other 198 




, within the SARS-CoV M protein have also been reported [17, 199 
21]. In another study looking at SARS-specific memory T cell responses in SARS-recovered 200 
individuals at 4 years post-infection, 28.75% of them presented T cell responses to M peptides [22], 201 
further supporting the role of M protein in eliciting dominant cellular immunity during SARS-CoV 202 
infection.  203 
3.3. Characterization of SARS-specific N53 CD8
+
 T cell response  204 
The SARS-CoV N protein is capable in inducing immunodominant T cell responses in SARS-205 
recovered individuals and these responses were shown to be involved in disease protection in animal 206 
models [23, 24]. In our previous study performed at 6 years post-SARS, several SARS-specific T cell 207 
epitopes within the N protein were reported [13]. In SARS subject 1 at 6 years post-infection, a HLA-208 
B*1525-restricted memory CD8
+
 T cell response targeting the N53 peptide, corresponding to residues 209 
261-275 of N protein, was detected. To determine the minimal epitope of the N53 CD8
+
 T cell 210 
response, truncated peptides were tested for induction of CD8
+
 T cell response using PBMCs from 211 
SARS subject 1 previously collected at 6 years post-infection. Truncated peptides consisted of 8- to 212 
10-mers within the 10 overlapping residues between N53 and N54 peptides, as the N54 peptide is also 213 
capable of inducing the response (data not shown). It was found that 10-mer peptide, N53266-275, 214 
corresponding to residues 266-275 of the N protein, was most efficient in inducing N53 T cell 215 
response of 12.7% (Table 3). Deletion of N-terminal threonine (T) residue and C-terminal 216 
phenylalanine (F) residue from N53266-275 led to decrease in percentages of IFNγ-producing CD8
+
 T 217 
cells to 10.9% and 8.0% respectively. This indicates that residues 266-275 is the minimal epitope of 218 
the N53 CD8
+
 T cell response. In previous study using bioinformatics NetMHCpan algorithm, the 219 
predicted minimal epitope for the N53 response was determined to be 9 amino acids at position 267-220 
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275 [25], which is within the 10-mer region identified in current study. Thus far, no other studies have 221 
reported the identification of the N53 CD8
+
 T cell epitope.  222 
3.4. Persistence of memory SARS-specific M29 and N53 CD8
+
 T cell responses at 11 years post-223 
infection 224 
Having characterized two CD8
+
 T cell responses at 6 and 9 years post-infection, the same 225 
donor was recalled at 11 years post-infection to determine the persistence of these responses.  PBMCs 226 
collected from the same individual were expanded in vitro using M29 and N53 minimal peptides 227 
(M29147-155 and N53266-275) and tested for CD8
+IFNγ+ responses. As shown in Figure 3 (left panel), 228 
when cells were stimulated with M29147-155 and N53266-275 peptides, CD8
+IFNγ+ T cell responses of 229 
0.4% and 0.9% were observed respectively,  suggesting the persistence of these SARS-specific 230 
memory T cells up to 11 year after infection. CD107a expression at 0.6% and 1.3% were also 231 
observed when cells were stimulated with M29147-155 and N53266-275 peptides respectively (Figure 3, 232 
right panels), indicating degranulation of T cells upon peptide stimulation. CD4
+
 T cell responses 233 
detected in SARS subject 1 at 9 years post-infection (Table 1) were undetectable at 11 years post-234 
infection (data not shown). 235 
3.5. Lack of cross-reactivity of SARS-specific M29 and N53 CD8
+
 T cell responses against 236 
MERS-CoV 237 
A novel human coronavirus, MERS-CoV, first emerged in 2012 [26, 27]. Like SARS-CoV, 238 
MERS-CoV is a betacoronavirus which causes serious and sometimes fatal lower respiratory tract 239 
infections and extrapulmonary manifestations [28, 29]. Contrary to SARS-CoV which is a lineage B 240 
betacoronavirus, MERS-CoV belongs to lineage C [30]. To investigate if SARS-specific M29 and 241 
N53 CD8
+
 T cells can cross-react with M and N peptides of MERS-CoV, sequence alignments were 242 
done to identify corresponding M29 and N53 minimal epitopes of MERS-CoV (Figure 4A and 4B). 243 
When M29- and N53-restimulated T cells were stimulated with MERS-CoV M29 minimal epitope 244 




responses were observed (Figure 4C), indicating the inability of these SARS-specific T cells to be 246 
activated by MERS-CoV peptides. Therefore, T cell immunity against SARS-CoV is highly specific 247 
and M29 and N53 CD8
+
 T cell responses are unlikely to provide cross-protection against MERS-CoV 248 
infection. This is expected as MERS-CoV is distantly related to SARS-CoV and is more closely 249 
related to other bat coronaviruses [30]. Nonetheless, sequence alignments revealed that the M29 and 250 
N53 minimal epitopes are fully conserved between human and zoonotic strains (Figure 4A and 4B), 251 
including civet SARS-CoV SZ3, bat SL-CoVs Rp3 and Rf1, and the bat SARS-CoV Rs3367 which is 252 
capable of utilizing both human and bat ACE2 receptors for cell entry [5]. Hence, it is likely that the 253 
SARS-specific M29 and N53 CD8
+
 T cells can confer cross-protection against infections of these 254 
zoonotic SARS-CoV and SL-CoV strains. 255 
4. Conclusion  256 
There are currently no reports on the persistence of memory T cells in SARS-recovered 257 
individuals beyond 6 years post-infection, therefore, the longevity of SARS-CoV cellular immunity is 258 
unclear. In this study, it was demonstrated that SARS-specific memory T cells persist in three SARS-259 
recovered individuals at 9 and 11 years post-SARS in the absence of antigen. All memory T cells 260 
detected were specific against SARS-CoV structural S, N and M proteins. Two immunodominant 261 
CD8
+
 T cell responses specific against M (M29) and N (N53) proteins were further characterized by 262 
defining the minimal epitope and HLA restriction. These CD8
+
 T cell responses continued to persist 263 
in a SARS-recovered subject up to 11 years post-infection. The persistence of T cell responses 264 
suggests that SARS-recovered patients could be protected from re-infection.  265 
Peptides of the replicase protein, which comprises 2/3 of the SARS-CoV proteome, were not 266 
included in memory T cell screening in the current study due to limited amount of SARS subject 267 
PBMCs obtained. However, based on current literature, the SARS-CoV replicase protein is less 268 
immunogenic compared to structural proteins [16]. It was also noted that the availability of three 269 
convalescent individuals is a significant constraint of this study. In future studies, the conclusions 270 
drawn here could be substantiated by including more SARS-recovered subjects.  271 
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In a Phase I clinical trial involving a SARS DNA vaccine encoding the S protein, SARS-272 
specific T cell responses were observed in vaccinated individuals, suggesting that the S protein is 273 
sufficiently to induce T cell responses [31]. In line with this, results in current study showed the long-274 
term persistence of T cell responses targeting the S protein, as well as other structural proteins 275 
including M and N proteins. This provides evidence for the design of SARS vaccines comprising of 276 
the viral structural proteins for the induction of dominant, potent and long-lived memory cellular 277 
responses against the virus.  278 
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Figure captions 370 
Figure 1. IFNγ ELISpot results for SARS-specific memory T cell screening. PBMCs from (A) a 371 
healthy individual and (B) SARS-recovered individual (SARS subject 1) were expanded in vitro using 372 
a mixture of SARS-CoV peptides, followed by IFNγ ELISpot assay using SARS peptide matrix pools 373 
of the structural (top panels) and accessory proteins (lower panels). Each bar represents the IFNγ-374 
producing response to an individual peptide matrix pool (numeric or alphabetic) in SFU per 5 x 10
4 375 
cells. The threshold for a positive response was set as two times above the mean SFU of unstimulated 376 
16 
 
cells (Neg), as indicated by the dotted line in the right panels. Cells stimulated with PMA/ionomycin 377 
were included as positive control (Pos).  378 
 379 
Figure 2. ICS and flow cytometry analysis of unstimulated and M29-stimulated T cells after 380 
restimulation using M29 peptide. The percentages of CD8
+ IFNγ+ and CD8+CD107a+ T cells shown 381 
represent the percentage of the T cells in total T cell population (after gating the CD3
+
 cells) present 382 
in the short-term T cell line obtained by restimulation using M29 peptide from SARS subject 1 at 9 383 
years post-infection. 384 
 385 
Figure 3. ICS and flow cytometry analysis of restimulated T cells from SARS subject 1 at 11 386 
years post-infection.  Percentages of CD8
+IFNγ+ responses (left panels)  and CD8+CD107a+ 387 
responses (right panels) of (A) unstimulated, (B) M29147-155-stimulated, (C) N53266-275-stimulated T 388 
cells are as indicated in the upper right quadrant of each dot plot. Percentage CD8
+ IFNγ+ cells shown 389 
represent the percentage of IFNγ-producing cells in the total T cell population (after gating the CD3+ 390 
cells) which were in vitro expanded in the presence of M29147-155 and N53266-275 peptides. 391 
 392 
Figure 4. Cross-reactivity of SARS-specific M29 and N53 CD8
+
 T cells. Sequence alignments of 393 
(A) M29 and (B) N53 regions of human SARS-CoV (HKU39849), civet SARS-CoV (SZ3), bat SL-394 
CoVs (Rp3, Rf1 and Rs3367) and MERS-CoV. (C) Percentages of CD8
+IFNγ+ T cell responses 395 
induced by SARS-CoV and MERS-CoV M29 (left) and N53 (right) minimal peptides. Percentage 396 
CD8
+ IFNγ+ cells shown represents the percentage of IFNγ-producing cells in the total T cell 397 
population (after gating the CD3
+
 cells) present in the short-term T cell line obtained by restimulation 398 
using SARS-CoV M29 and N53 minimal peptides (M29147-155 and N53266-275) from SARS subject 1 at 399 
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Table 1. Summary of T cell responses in SARS-recovered subjects at 9 or 11 years post-infection, 402 
identified from screening by ELISpot and confirmation by ICS. Percentages of T cell responses 403 




 T cells over total T cell population after in vitro expansion in the 404 

















IFNγ+ T cells  
M29  15-mer  141 - 155         AVIIR GHLRM AGHSL  5.3%  
M29144-155  12-mer  144 - 155                IR GHLRM AGHSL  14.8%  
M29143-154  12-mer  143 - 154            IIR GHLRM AGHS  0.2%  
M29145-155  11-mer  145 - 155                 R GHLRM AGHSL  17.8%  
M29146-155  10-mer  146 -155                    GHLRM AGHSL  22.8%  
M29145-154  10-mer  145 - 154              R GHLRM AGHS  0.2%  
M29147-155  9-mer  147 -155                      HLRM AGHSL  32.9%  
M29148-155  8-mer  148 - 155                        LRM AGHSL  0.3%  
Unstimulated cells  0.2%  
PMA/Ionomycin-stimulated cells  11.1%  
Table 2. Summary of percentage CD8
+ IFNγ+ responses in SARS subject 1 induced by truncated 412 
peptides within M29 region. T cells used were obtained from SARS subject 1 at 9 years post-413 
infection. Results of positive peptides (M29, M29144-155, M29145-155, M29146-155, M29147-155) and 414 
selected negative peptides (M29143-154, M29145-154, M29148-155) are shown. Percentage CD8
+IFNγ+ T 415 
cells shown represents the percentage of IFNγ-producing CD8+ T cells in the total T cell population 416 
(after gating the CD3
+
 cells) present in the short-term T cell line obtained by restimulation using M29 417 
















IFNγ+ T cells  
N53  15-mer  261 - 275  QKRTA TKQYN VTQAF  8.8%  
N53
266-275 
 10-mer  266 - 275                      TKQYN VTQAF  12.7%  
N53
266-274 
 9-mer  266 - 274                      TKQYN VTQA  8.0%  
N53
267-275 
 9-mer  267  -275                  KQYN VTQAF  10.9%  
N53
266-273 
 8-mer  266 - 273                      TKQYN VTQ  2.2%  
N53
267-274 
 8-mer  267 - 274                        KQYN VTQA  2.3%  
N53
268-275 
 8-mer  268 - 275                     QYN VTQAF  2.2%  
Unstimulated cells  1.6%  
PMA/Ionomycin-stimulated cells  15.3%  
Table 3. Summary of percentage CD8
+IFNγ+ responses in SARS subject 1 induced by truncated 424 
peptides within N53 region. T cells used were obtained from SARS subject 1 at 6 years post-425 
infection. Percentage of CD8
+IFNγ+ cells shown represent the percentage of IFNγ-producing CD8+ 426 
cells in the total T cell population (after gating the CD3
+
 cells) present in the short-term T cell line 427 
obtained from restimulation using N53 peptide. The minimal epitope is indicated in italics. 428 
Figure 1. IFNγ ELISpot results for SARS-specific memory T cell screening. PBMCs from (A) a healthy individual and (B) SARS-
recovered individual (SARS subject 1) were expanded in vitro using a mixture of SARS-CoV peptides, followed by IFNγ ELISpot 
assay using SARS peptide matrix pools of the structural (top panels) and accessory proteins (lower panels). Each bar 
represents the IFNγ-producing response to an individual peptide matrix pool (numeric or alphabetic) in SFU per 5 x 104 cells. 
The threshold for a positive response was set as two times above the mean SFU of unstimulated cells (Neg), as indicated by 
the dotted line in the right panels. Cells stimulated with PMA/ionomycin were included as positive control (Pos).  
Figure 2. ICS and flow cytometry analysis of unstimulated and M29-stimulated T cells after restimulation using M29 
peptide. The percentages of CD8+ IFNγ+ and CD8+CD107a+ T cells shown represent the percentage of the T cells in total T cell 
population (after gating the CD3+ cells) present in the short-term T cell line obtained by restimulation using M29 peptide 
from SARS subject 1 at 9 years post-infection. 
Figure 3. ICS and flow cytometry analysis of 
restimulated T cells from SARS subject 1 at 11 
years post-infection.  Percentages of CD8+IFNγ+ 
responses (left panels)  and CD8+CD107a+ 
responses (right panels) of (A) unstimulated, (B) 
M29147-155-stimulated, (C) N53266-275-stimulated T 
cells are as indicated in the upper right quadrant 
of each dot plot. Percentage CD8+ IFNγ+ cells 
shown represent the percentage of IFNγ-
producing cells in the total T cell population (after 
gating the CD3+ cells) which were in vitro 
expanded in the presence of M29147-155 and 
N53266-275 peptides. 
  
Figure 4. Cross-reactivity of SARS-specific M29 and 
N53 CD8+ T cells. Sequence alignments of (A) M29 
and (B) N53 regions of human SARS-CoV 
(HKU39849), civet SARS-CoV (SZ3), bat SL-CoVs (Rp3, 
Rf1 and Rs3367) and MERS-CoV. (C) Percentages of 
CD8+IFNγ+ T cell responses induced by SARS-CoV and 
MERS-CoV M29 (left) and N53 (right) minimal 
peptides. Percentage CD8+ IFNγ+ cells shown 
represents the percentage of IFNγ-producing cells in 
the total T cell population (after gating the CD3+ 
cells) present in the short-term T cell line obtained 
by restimulation using SARS-CoV M29 and N53 
minimal peptides (M29147-155 and N53266-275) from 
SARS subject 1 at 9 years post-infection.  
Supplementary materials 
Protein  Matrix  
(number of numeric pools 




Total number of peptides in matrix  
S  16 + 16  32  249  
E / M  7 + 9  16  57  
(14 E peptides;  
43 M peptides)  
N  9 + 9  18  82  
3a  7 + 8  15  53  
3b / 6  6 + 7  13  40  
(29 3b peptides;  
11 6 peptides)  
7a / 7b  5 + 6  11  30  
(23 7a peptides;  
7b peptides)  
8a / 8b / 9b  6 + 7 13  39  
(6 8a peptides;  
15 8b peptides; 
18 ORF9 peptides)  
Supplementary Table 1. Pooling of 550 SARS-CoV peptides spanning the proteome of the 
structural (S, N, M and E) and accessory (3a, 3b, 6, 7a, 7b, 8a, 8b, 9b) proteins used for ELISpot 
assay. 15-mer peptides within each protein are arranged in matrices consisting of numeric and 





 Clinical presentation Treatment Days before 
fever 
subsided 
SARS subject 1  Patient had hypoxemia and required oxygen 
supplementation. Patient’s chest radiography showed 
worsening bilateral opacifications. Laboratory 
abnormalities included elevated levels of aspartate 
aminotransferase and lactate dehydrogenase and an 
elevated maximal C-reactive protein level as well as 








SARS subject 2 Patient had dry cough and hypoxemia. There were 
crackles over the patient’s lungs. Laboratory 
abnormalities included an elevated maximal C-





SARS subject 3 Patient’s chest radiography showed a left midzone 
pulmonary infiltrate and computed tomography of 
the thorax confirmed the presence of the pulmonary 
infiltrate in the apical segment of the left lower lobe. 
Patient's respiratory status remained stable and no 







Supplementary Table 2. Clinical information of the SARS-recovered subjects recruited in this 
study. Some of these information were previously published by Drosten et al. (N Engl J Med 2003; 
348:1967-1976) and Lim et al. (N Engl J Med 2004; 350:1740-1745.).  
 
